Ondine Biomedical, Inc. OBI
LSE · United Kingdom · Health Technology
GBp 9.750.00 (0.00%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the developer of light-activated nasal disinfection for hospital patients, has suspended trading in its shares while it raises new investment to capitalise on its clinical and commercial progress. The company is one of a growing band of growth...
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has won support from Peel Hunt after partnering with Mela Solutions to accelerate access for its Steriwave infection-prevention technology across NHS intensive care units. Peel Hunt retained its ‘buy’ rating and 29p price target, highlighting the...
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has teamed up with Mela Solutions, whose software sits in 90% of NHS intensive care units, to help hospitals test whether its Steriwave system saves them money. Steriwave uses light to activate an antimicrobial treatment applied inside the nose,...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.